Criteria for clinical stability in hospitalised patients with community-acquired pneumonia

European Respiratory Journal

Volumn 42, Issue 3, 2013, Pages 742-749

  Aliberti, Stefano ^a,b   Zanaboni, Anna Maria ^c   Wiemken, Tim ^b   Nahas, Ahmed ^b   Uppatla, Srinivas ^b   Morlacchi, Letizia Corinna ^c   Peyrani, Paula ^b   Blasi, Francesco ^c   Ramirez, Julio ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH STATUS; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

AGED; COMMUNITY-ACQUIRED INFECTIONS; COUGH; DYSPNEA; FEMALE; FEVER; HEART RATE; HOSPITALIZATION; HOSPITALS, VETERANS; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; OXIMETRY; PNEUMONIA; RESPIRATORY RATE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84883493860     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00100812     Document Type: Article

References (22)

1. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754. (Pubitemid 32578779)
2. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-1276.
3. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-2454. (Pubitemid 29526773)
4. Division of Anti-infective Products/Office of Antimicrobial Products. Anti-Infective Drugs Advisory Committee. Endpoints and Clinical Trial Issues in Community-Acquired Bacterial Pneumonia. www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/anti- infectivedrugsadvisorycommittee/ucm275823.pdf Date last accessed: May 15, 2012. Date last updated: November 3, 2011.
5. Musher DM. Clinical and microbiological end points in the treatment of pneumonia. Clin Infect Dis 2008; 47: Suppl. 3, S207-S209.
6. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72. (Pubitemid 46290553)
7. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 1452-1457. (Pubitemid 28228202)
8. Ramirez JA. Fostering international multicenter collaborative research: the CAPO Project. Int J Tuberc Lung Dis 2007; 11: 1062-1065. (Pubitemid 47605394)
9. Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008; 134: 955-962.
10. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250. (Pubitemid 27044625)
11. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community-acquired pneumonia: a validation study. Thorax 2000; 55: 219-223. (Pubitemid 30245972)
12. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
13. Schuetz P, Amin DN, Greenwald JL. Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 2012; 141: 1063-1073.
14. Menéndez R, Martinez R, Reyes S, et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009; 64: 987-992.
15. Gómez J, Baños V, Ruiz Gómez J, et al. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996; 15: 556-560. (Pubitemid 26273211)
16. Menéndez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63: 447-452. (Pubitemid 351692355)
17. Guertler C, Wirz B, Christ-Crain M, et al. Inflammatory responses predict long-term mortality risk in communityacquired pneumonia. Eur Respir J 2011; 37: 1439-1446.
18. Jasti H, Mortensen EM, Obrosky DS, et al. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2008; 46: 550-556. (Pubitemid 351263494)
19. Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278-1284. (Pubitemid 34595034)
20. Capelastegui A, España PP, Bilbao A, et al. Pneumonia: criteria for patient instability on hospital discharge. Chest 2008; 134: 595-600.
21. Capelastegui A, España PP, Quintana JM, et al. Declining length of hospital stay for pneumonia and postdischarge outcomes. Am J Med 2008; 121: 845-852.
22. Aliberti S, Peyrani P, Filardo G, et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest 2011; 140: 482-488.